

Electronic Acknowledgement Receipt

EFS ID:	5938417
Application Number:	10502403
International Application Number:	
Confirmation Number:	3497
Title of Invention:	Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
First Named Inventor/Applicant Name:	Jose Manuel Francisco Ochoa
Customer Number:	26111
Filer:	Lori Mau Brandes
Filer Authorized By:	
Attorney Docket Number:	2099.0090000
Receipt Date:	24-AUG-2009
Filing Date:	20-JUN-2005
Time Stamp:	16:50:22
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$310
RAM confirmation Number	4384
Deposit Account	
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	-------------------------------------	------------------	------------------

1	Foreign Reference	FP1WO97017975.pdf	729444 0d18b41e521a75a78a8b9801adfc2e019b735478be1	no	25
Warnings:					
Information:					
2	Foreign Reference	FP2WO00040233.pdf	847518 996407c1d86327e0f9f18b1751a1e1ed7b14d	no	17
Warnings:					
Information:					
3	Foreign Reference	FP3WO01032158.pdf	3027168 8e5798f2c4b18a0b684817a9f251d1921c7f0789	no	76
Warnings:					
Information:					
4	Foreign Reference	FP4WO03061643.pdf	576734 381b78cac1958955e4918b1259e012c7511d89138	no	16
Warnings:					
Information:					
5	Foreign Reference	FP5WO04045622.pdf	1960199 e087541723eed279b59b8c664041b7b0cc9406	no	38
Warnings:					
Information:					
6	NPL Documents	NPL1AbbinkDiabetMed2002.pdf	552427 37ddde11c1b809e08b4d05cd8c5de3289be1641c	no	11
Warnings:					
Information:					
7	NPL Documents	NPL2BresslerArchInternMed1997.pdf	1445060 2cad0e09619a0104b6a5a557199cc1ab5ef8d4	no	16
Warnings:					
Information:					
8	NPL Documents	NPL3CefaluDiabetolgia1996.pdf	460669 570d0cc1fa1b2a07b6e67ae2a120813eb0d63955c	no	4
Warnings:					
Information:					
9	NPL Documents	NPL4CefaluDiabetes1996.pdf	444375 14695011b26e99c237f8c32a564020e0765348e51	no	4
Warnings:					
Information:					

10	NPL Documents	NPL5CharpentierDiabetMed201.pdf	1002752 ca58399f7023713a46d90bce91fb208ebb842	no	10
Warnings:					
Information:					
11	NPL Documents	NPL6CrouseCirculation1996.pdf	445744 51c6b6a39ac21856f6d602c9c24ac0f510c96d1	no	4
Warnings:					
Information:					
12	NPL Documents	NPL7DagogoJackArchInternMed1997.pdf	4281112 244fb905d8702ae12ae16c94c771ne70b11e1fca702	no	19
Warnings:					
Information:					
13	NPL Documents	NPL8DeFronzoAnnInternMed1999.pdf	3673515 a18731e13ce998cf722f6025ceae66d231b3	no	26
Warnings:					
Information:					
14	NPL Documents	NPL11GonzalezOrtizRevistaInvestClinica2004.pdf	600486 6d81a2218a493624c19ac2750c5c6d680e4264c	no	7
Warnings:					
Information:					
15	NPL Documents	NPL12EnglishTranslationofGonzalezOrtizRevistaInvestClinica2004.pdf	489919 33a8c6dcecd02b6c64a7b3d6a41bce5ef8ce9	no	9
Warnings:					
Information:					
16	NPL Documents	NPL13GonzalezOrtizJDiabetCompl2008.pdf	675006 983c6c5c940a5ab970d116c8da0b8bc75253ba1	no	4
Warnings:					
Information:					
17	NPL Documents	NPL14GomisEndocrine2000.pdf	737262 6a7e612a57832d1949152bec5406c103f2ee96	no	8
Warnings:					
Information:					
18	NPL Documents	NPL16Higginbothametal.pdf	290609 095a8bdc75f762b6c9c52a30599f11eb3a2280	no	5
Warnings:					
Information:					

19	NPL Documents	NPL17HolsteinDiabetologia2000.pdf	284542 76d88c287d8d4184007ce98c520236d5112538d7	no	4
Warnings:					
Information:					
20	NPL Documents	NPL18MullerBiochimicaBiophysicaActa1999.pdf	976556 8380d8dd1516dd978d637cf1d5ac656874ee8f6c	no	13
Warnings:					
Information:					
21	NPL Documents	NPL19RosenstockJSamolsE.pdf	963852 c73cc7ba78f6d6195a1c179865081c3a934fb7	no	9
Warnings:					
Information:					
22	NPL Documents	NPL20SatoExcerptaMedica1994.pdf	756942 d13e2e598f6a55a14e7eb2b18d83c25d21e82a	no	6
Warnings:					
Information:					
23	NPL Documents	NPL21ScheenDrugs1998.pdf	2180924 e3ed428dc2de5ec97043995993e31f826446db	no	15
Warnings:					
Information:					
24	NPL Documents	NPL22SiftonPhysiciansDeskReference2000.pdf	1027031 2b1f3c1794195ebdb948f76ec21f586119cd4dd	no	6
Warnings:					
Information:					
25	NPL Documents	NPL23SonnenbergAnnPharmacother1997.pdf	1216892 3818287bc42216dd7888f12d2702642df13ee8c8	no	9
Warnings:					
Information:					
26	NPL Documents	NPL24Vignieretal.pdf	1885218 474168c0b624ba112ee037a69d3036d20216c72	no	6
Warnings:					
Information:					
27	NPL Documents	NPL25ISRPTMX020003.pdf	576734 31857a223b49f1d4de2f28f3638ba370ffae317c	no	16
Warnings:					
Information:					

28	NPL Documents	NPL26IPERPCTMX020003.pdf	68272 47793818eb0c9813a8f08b46c5c805ab1ec6801	no	2
Warnings:					
Information:					
29	NPL Documents	NPL27DighoreIntJPharmTechRes2009.pdf	236487 4b111106c1949510b7000067a13a242025559829	no	13
Warnings:					
Information:					
30		20990090000IDSfiling.pdf	3136047 147ae0719c1908f6c743a7090ea0c0c70194ae70b	yes	56
Multipart Description/PDF files in .zip description					
Document Description		Start	End		
Miscellaneous Incoming Letter		1	2		
Extension of Time		3	3		
Amendment/Req. Reconsideration-After Non-Final Reject		4	4		
Applicant Arguments/Remarks Made in an Amendment		5	48		
Transmittal Letter		49	52		
Information Disclosure Statement (IDS) Filed (SB/08)		53	56		
Warnings:					
Information:					
31	NPL Documents	20990090000NPL9.pdf	975584 65cbe0b0ba69e6b782594758ab3c0820fb315225	no	10
Warnings:					
Information:					
32	NPL Documents	20990090000NPL10.pdf	738285 c6075e10754eb5a6e756e4436c60f1b59143eab8	no	8
Warnings:					
Information:					
33	NPL Documents	20990090000NPL15.pdf	829919 1b8da19075a03044a63e4e0954c6c03472b4c1c	no	11
Warnings:					
Information:					

34	Fee Worksheet (PTO-875)	fee-info.pdf	31807 95796263446687d7d3c878ba1028ca5c4d5c a10d	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			38125091		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					